Many people notice reduced appetite within the first few weeks, but meaningful weight loss builds gradually over months as the dose increases
Its believed that this is because the medications reduce levels of IL-6 (interleukin 6), tumor necrosis factor-a (TNF-a) and high-sensitivity C-reactive protein (hsCRP)
Patients with specific GIPR variants may experience dramatically amplified benefits from tirzepatide's GIP activation, while others show stronger GLP-1 pathway responsiveness favoring semaglutide
Interestingly, The New York Times recently spotlighted an intriguing side effect of the GLP-1 weight-loss drug boom: lighter airplanes (January 19, 2026)
This was a fairly small study and a lot of questions remain to be answered, including whether GLP-1 agonists could help people with more advanced Parkinsons, halt the progression of Parkinsons motor symptoms over a longer period, or prevent other types of symptoms, such as ones related to cognition, from worsening